Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase

Dun Yang, Hong Liu, Andrei Goga, Suwon Kim, Mariia Yuneva, J. Michael Bishop

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

The Myc protein and proteins that participate in mitosis represent attractive targets for cancer therapy. However, their potential is presently compromised by the threat of side effects and by a lack of pharmacological inhibitors of Myc. Here we report that a circumscribed exposure to the aurora kinase inhibitor, VX-680, selectively kills cells that overexpress Myc. This synthetic lethal interaction is attributable to inhibition of aurora-B kinase, with consequent disabling of the chromosomal passenger protein complex (CPPC) and ensuing DNA replication in the absence of cell division; executed by sequential apoptosis and autophagy; not reliant on the tumor suppressor protein p53; and effective against mouse models for B-cell and T-cell lymphomas initiated by transgenes of MYC. Our findings cast light on how inhibitors of aurora-B kinase may kill tumor cells, implicate Myc in the induction of a lethal form of autophagy, indicate that expression of Myc be a useful biomarker for sensitivity of tumor cells to inhibition of the CPPC, dramatize the virtue of bimodal killing by a single therapeutic agent, and suggest a therapeutic strategy for killing tumor cells that overexpress Myc while sparing normal cells.

Original languageEnglish (US)
Pages (from-to)13836-13841
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number31
DOIs
StatePublished - Aug 3 2010

Fingerprint

Aurora Kinase B
Proto-Oncogenes
Autophagy
Proteins
Aurora Kinases
Tumor Suppressor Protein p53
Therapeutics
Neoplasms
T-Cell Lymphoma
Tumor Biomarkers
DNA Replication
Transgenes
Mitosis
Cell Division
B-Lymphocytes
Inhibition (Psychology)
Pharmacology
Apoptosis

Keywords

  • Apoptosis
  • Aurora kinase
  • Autophagy synthetic lethality
  • Chromosomal passenger protein complex
  • Targeted therapy

ASJC Scopus subject areas

  • General

Cite this

Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. / Yang, Dun; Liu, Hong; Goga, Andrei; Kim, Suwon; Yuneva, Mariia; Bishop, J. Michael.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 31, 03.08.2010, p. 13836-13841.

Research output: Contribution to journalArticle

@article{c6c919e35f7d47a0a66723534c6926e6,
title = "Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase",
abstract = "The Myc protein and proteins that participate in mitosis represent attractive targets for cancer therapy. However, their potential is presently compromised by the threat of side effects and by a lack of pharmacological inhibitors of Myc. Here we report that a circumscribed exposure to the aurora kinase inhibitor, VX-680, selectively kills cells that overexpress Myc. This synthetic lethal interaction is attributable to inhibition of aurora-B kinase, with consequent disabling of the chromosomal passenger protein complex (CPPC) and ensuing DNA replication in the absence of cell division; executed by sequential apoptosis and autophagy; not reliant on the tumor suppressor protein p53; and effective against mouse models for B-cell and T-cell lymphomas initiated by transgenes of MYC. Our findings cast light on how inhibitors of aurora-B kinase may kill tumor cells, implicate Myc in the induction of a lethal form of autophagy, indicate that expression of Myc be a useful biomarker for sensitivity of tumor cells to inhibition of the CPPC, dramatize the virtue of bimodal killing by a single therapeutic agent, and suggest a therapeutic strategy for killing tumor cells that overexpress Myc while sparing normal cells.",
keywords = "Apoptosis, Aurora kinase, Autophagy synthetic lethality, Chromosomal passenger protein complex, Targeted therapy",
author = "Dun Yang and Hong Liu and Andrei Goga and Suwon Kim and Mariia Yuneva and Bishop, {J. Michael}",
year = "2010",
month = "8",
day = "3",
doi = "10.1073/pnas.1008366107",
language = "English (US)",
volume = "107",
pages = "13836--13841",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "31",

}

TY - JOUR

T1 - Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase

AU - Yang, Dun

AU - Liu, Hong

AU - Goga, Andrei

AU - Kim, Suwon

AU - Yuneva, Mariia

AU - Bishop, J. Michael

PY - 2010/8/3

Y1 - 2010/8/3

N2 - The Myc protein and proteins that participate in mitosis represent attractive targets for cancer therapy. However, their potential is presently compromised by the threat of side effects and by a lack of pharmacological inhibitors of Myc. Here we report that a circumscribed exposure to the aurora kinase inhibitor, VX-680, selectively kills cells that overexpress Myc. This synthetic lethal interaction is attributable to inhibition of aurora-B kinase, with consequent disabling of the chromosomal passenger protein complex (CPPC) and ensuing DNA replication in the absence of cell division; executed by sequential apoptosis and autophagy; not reliant on the tumor suppressor protein p53; and effective against mouse models for B-cell and T-cell lymphomas initiated by transgenes of MYC. Our findings cast light on how inhibitors of aurora-B kinase may kill tumor cells, implicate Myc in the induction of a lethal form of autophagy, indicate that expression of Myc be a useful biomarker for sensitivity of tumor cells to inhibition of the CPPC, dramatize the virtue of bimodal killing by a single therapeutic agent, and suggest a therapeutic strategy for killing tumor cells that overexpress Myc while sparing normal cells.

AB - The Myc protein and proteins that participate in mitosis represent attractive targets for cancer therapy. However, their potential is presently compromised by the threat of side effects and by a lack of pharmacological inhibitors of Myc. Here we report that a circumscribed exposure to the aurora kinase inhibitor, VX-680, selectively kills cells that overexpress Myc. This synthetic lethal interaction is attributable to inhibition of aurora-B kinase, with consequent disabling of the chromosomal passenger protein complex (CPPC) and ensuing DNA replication in the absence of cell division; executed by sequential apoptosis and autophagy; not reliant on the tumor suppressor protein p53; and effective against mouse models for B-cell and T-cell lymphomas initiated by transgenes of MYC. Our findings cast light on how inhibitors of aurora-B kinase may kill tumor cells, implicate Myc in the induction of a lethal form of autophagy, indicate that expression of Myc be a useful biomarker for sensitivity of tumor cells to inhibition of the CPPC, dramatize the virtue of bimodal killing by a single therapeutic agent, and suggest a therapeutic strategy for killing tumor cells that overexpress Myc while sparing normal cells.

KW - Apoptosis

KW - Aurora kinase

KW - Autophagy synthetic lethality

KW - Chromosomal passenger protein complex

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77956369534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956369534&partnerID=8YFLogxK

U2 - 10.1073/pnas.1008366107

DO - 10.1073/pnas.1008366107

M3 - Article

C2 - 20643922

AN - SCOPUS:77956369534

VL - 107

SP - 13836

EP - 13841

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 31

ER -